JPS59500272A - 抗ガン剤 - Google Patents

抗ガン剤

Info

Publication number
JPS59500272A
JPS59500272A JP58500586A JP50058683A JPS59500272A JP S59500272 A JPS59500272 A JP S59500272A JP 58500586 A JP58500586 A JP 58500586A JP 50058683 A JP50058683 A JP 50058683A JP S59500272 A JPS59500272 A JP S59500272A
Authority
JP
Japan
Prior art keywords
monensin
substances
antitoxic
substance
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP58500586A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0534343B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
ジエンセン，フランツ
グロス，ピエ−レ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JPS59500272A publication Critical patent/JPS59500272A/ja
Publication of JPH0534343B2 publication Critical patent/JPH0534343B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP58500586A 1982-02-09 1983-02-04 抗ガン剤 Granted JPS59500272A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8202091A FR2521010B1 (fr) 1982-02-09 1982-02-09 Medicaments comportant en tant qu'association au moins une immunotoxine et au moins un ionophore carboxylique monovalent
FR82/02091FR 1982-02-09

Publications (2)

Publication Number Publication Date
JPS59500272A true JPS59500272A (ja) 1984-02-23
JPH0534343B2 JPH0534343B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-05-21

Family

ID=9270809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58500586A Granted JPS59500272A (ja) 1982-02-09 1983-02-04 抗ガン剤

Country Status (8)

Country Link
US (1) US4767621A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0086152B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS59500272A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE19857T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3363563D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2521010B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO833641L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1983002725A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
FR2564839B1 (fr) * 1984-05-23 1986-11-14 Sanofi Sa Conjugues associant par liaison covalente un ionophore carboxylique monovalent et une macromolecule et leur utilisation comme agents potentialisateurs des immunotoxines
CA1314245C (en) * 1984-05-23 1993-03-09 Franz Jansen Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
IL116559A (en) * 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
US20190046497A1 (en) * 2016-02-14 2019-02-14 Yeda Research And Development Co., Ltd. Methods of modulating protein exocytosis and uses of same in therapy

Also Published As

Publication number Publication date
EP0086152B1 (fr) 1986-05-21
US4767621A (en) 1988-08-30
WO1983002725A1 (en) 1983-08-18
FR2521010B1 (fr) 1985-07-19
JPH0534343B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-05-21
EP0086152A1 (fr) 1983-08-17
NO833641L (no) 1983-10-06
FR2521010A1 (fr) 1983-08-12
ATE19857T1 (de) 1986-06-15
DE3363563D1 (en) 1986-06-26

Similar Documents

Publication Publication Date Title
Selbo et al. In vivo documentation of photochemical internalization, a novel approach to site specific cancer therapy
Hosmane Boron and gadolinium neutron capture therapy for cancer treatment
Peroutka et al. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions
Cao et al. Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy
Neuwelt et al. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity
Gurnari et al. When poisons cure: the case of arsenic in acute promyelocytic leukemia
ATA21888A (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
ES469878A1 (es) Un procedimiento para preparar una composicion farmaceutica para el tratamiento del habito de consumir drogas
Ariel Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors
JPS59500272A (ja) 抗ガン剤
SU263807A1 (ru) Новый способ лечени анемии и озены
WO2018078648A4 (en) Gold nanoparticle based formulation for use in cancer therapy
Yoxall Pain in small animals–its recognition and control
Rubens Antibodies as carriers of anticancer agents
JPS59500370A (ja) 免疫毒素とクロロキンとの組合せからなる細胞毒性薬剤
Blakey et al. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug
DE3344086C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2019244954A1 (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン１０薬剤
Karamanou et al. Arsenic powder in the treatment of cancer: the invention of French physician Pierre Alliot (1610–1685)
DE3689299T2 (de) Verwendung von amphipatischen Molekülen zur Radiodarstellung und Therapie mittels monoklonaler oder polyklonaler Antikörperkonjugate.
Tobin Pharmacology Review: Streptomycin, Gentamicin and the Arninoglycoside Antibiotics
DE69005874T2 (de) Verwendung von Tetrachloroplatinatkomplexen mit Diazofarbstoffen als Antikrebsmittel.
CA1205386A (en) Drugs containing a psoralene derivative
JP7684719B2 (ja) 腫瘍に対する免疫を賦活させるための医薬組成物及びその方法
Skolnick First immunotoxin therapy for many common solid tumors enters phase I clinical trial